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Abstract
PURPOSE—Determine if quantitative analyses (“radiomics”) of low dose CT lung cancer 
screening images at baseline can predict subsequent emergence of cancer.
PATIENTS AND METHODS—Public data from the National Lung Screening Trial (ACRIN 
6684) were assembled into two cohorts of 104 and 92 patients with screen detected lung cancer 
(SDLC), then matched to cohorts of 208 and 196 screening subjects with benign pulmonary 
nodules (bPN). Image features were extracted from each nodule and used to predict the subsequent 
emergence of cancer.
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RESULTS—The best models used 23 stable features in a Random Forest classifier, and could 
predict nodules that will become cancerous 1 and 2 years hence with accuracies of 80% (AUC 
0.83) and 79% (AUC 0.75), respectively. Radiomics outperformed Lung-RADS and volume. 
McWilliams’ risk assessment model was commensurate.
CONCLUSION—Radiomics of lung cancer screening CTs at baseline can be used to assess risk 
for development of cancer.
Keywords
Screening; Radiomics; Lung Cancer
Introduction
Lung cancer is the leading cause of cancer-related death in the US and worldwide1,2. 
Because of the large number of affected individuals, improvements in diagnosis at an early, 
potentially curable stage would have a major impact on human health. The National Lung 
Screening Trial (NLST) compared low-dose computed tomography (CT) to standard chest 
radiography (CXR) across three annual screens. There were 309 deaths per 100,000 person-
years in the CXR group and 247 deaths per 100,000 person-years in the low dose CT group 
representing a 20% relative reduction in lung cancer mortality within the CT arm compared 
to CXR3. Of the CT-detected lung cancers, 58% had a prior nodule-positive screen that was 
not determined to be lung cancer (i.e., nodule positive/cancer negative)4. An important issue 
that arose from these studies was the high detection of 4 to 12 mm diameter indeterminate 
pulmonary nodules (IPNs) that were “suspicious”, but not diagnosed as cancer. Of the IPNs, 
96.4% were not diagnosed as, or did not develop into, cancers during the screening period or 
follow-up. Hence, only 3.6% of IPNs were nascent cancers5. Overdiagnosis as “suspicious” 
is harmful because of patient anxiety, and a subsequent work-up or treatment of these 
cancers can incur unnecessary costs and morbidity for a condition that may pose no threat if 
not otherwise treated.5,6
The present work tests the hypothesis that quantitative image features (“radiomics”) can 
accurately predict whether an IPN at baseline, T0, will subsequently present as a clinically 
relevant cancer at the first, T1, or second follow-up, T2. Radiomics treats medical images as 
data that can be mined for information. To investigate the hypothesis, we created 
demographically-matched cohorts of CT screening subjects with IPNs that did, or did not 
subsequently develop into cancers. Two hundred and nineteen 3-D image features describing 
size, shape, location and texture were extracted from segmented volumes and prioritized to 
develop predictive classifier models that could predict incidence lung cancer after the 
baseline screen.
Materials and Methods
NLST Study Population
Data and images from the NLST were accessed through the NCI Cancer Data Access 
System7. The study design and main findings of the NLST have been described previously3. 
Briefly, 53,454 current or former smokers between 55 and 74 years of age were enrolled at 
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33 U.S medical centers. The participants were randomly assigned to the LDCT-arm (26,722 
subjects) or CXR-arm and asked to undergo a baseline and two annual follow-up screenings. 
CT images were downloaded and a trained radiologist (H.W.) identified the nodules of 
interest and ensured correct matching across annual scans.
Screen-detected lung cancer patients and nodule-positive/cancer-free participants
As described in Schabath et al.8, we restructured the entire CT arm of the NLST according 
to screening histories. Based on the NLST protocol, a positive screen was defined as non-
calcified nodule ≥ 4 mm in the axial plane or, less commonly, other abnormalities such as 
adenopathy or pleural effusion. Six different screen-detected lung cancer patient cohorts 
were defined based on specific sequences of screening results. For this analysis, we focused 
on two screen-detected lung cancer (SDLC) patient cohorts described in Figure 1. Both 
patient groups had baseline (T0) positive screens not associated with a lung cancer 
diagnosis. Individuals in the SDLC cohort 1 had a screen-detected lung cancer at the first 
follow-up screen (T1); SDLC 2 had positive screens at T0 and T1 and a screen-detected lung 
cancer at the second follow-up screen (T2), which was approximately two years after the 
baseline screen. Complications with segmentation as described in Supplemental Table 1 led 
to there being 85 patients each in SDLC1 and SDLC2.
To compare incidence lung cancer cases to cancer-free (controls) screening participants, we 
identified two cancer-free cohorts with benign pulmonary nodules [bPN] that were 
frequency matched 2:1 to the SDLCs on demographic characteristics and risk factors (i.e., 
age [± 5 years], sex, smoking status, and pack-years smoked [± 5 pack-years]). bPN cohorts 
-1 and -2 contained 208 and 184 subjects, respectively. Of these, 176 nodules from bPN 
cohort 1 and 152 nodules from bPN cohort 2 were successfully segmented and hence, 
available for subsequent radiomic feature extraction. Segmentation complications include 
calcification, or the nodule being attached to the pleural wall (Supplemental Table 1). Some 
of these challenges with spiculated and semi-solid nodules can be overcome when better 
segmentation algorithms are developed. This nested, matched study design minimizes the 
influence of confounders and risk factors between lung cancer patients and bPN subjects. 
Full demographic and clinical descriptors of these cohorts are provided in Table 1. The 
NLST database-specific patient I.D.’s are provided in Supplemental Table 2. At baseline, 
there was a trend to larger size in the cohort that eventually presented with cancer. The 
average ± SD of the longest diameters were: 8.06 ± 3.45 mm for bPN1 and 8.6 ± 3.85 mm 
for bPN2, and 12.07 ± 5.35 mm for SDLC1 and 12.086 ± 9.89 for SDLC2. Although these 
differences were significant, the multivariate approach increased predictive accuracy.
Target lung nodule identification
Two radiologists reviewed all CT images at both the lung window setting (width, 1500 HU; 
level, -600 HU) and mediastinal window setting (width, 350 HU; level, 40 HU). The 
identification of cancerous nodules in SDLC cohorts was based on the tables provided by the 
NLST with information about the location, size, and histology for those that were resected. 
Nodule location wasn’t always available for bPN cohorts. In these cases, the head radiologist 
(Y.L.) identified the suspicious 4–12 mm diameter IPN using prior experience. For those 
cases with multiple lung nodules, any nodule with diameter of more than 4 mm in a lung 
Hawkins et al. Page 3
J Thorac Oncol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
window setting was identified. The locations of all nodules in this study have been made 
available in the TCIA database (www.cancerimagingarchive.net). The largest nodule at time 
0 was used for feature extraction.
Patients diagnosed with cancer at T1 or T2 were placed into separate cohorts based on their 
screening history (Figure 1) and their baseline T0 scans were analyzed. Supplemental Table 
3, shows 270 prevalent cases of cancer at the first screen, and 196 SDLCs were identified 
following a prior positive scan, compared to 125 SDLCs following nodule-negative screens, 
and 44 interval cases diagnosed incidentally before the next screening8.
Segmentation
Slice numbers of cancerous nodules were provided by NLST and reviewed by radiologists 
(L.Y., Q.L.), who provided additional anatomical locations for use during segmentation. 
Nodules were segmented in 3D with our single-click ensemble segmentation approach9, 
running on a LuTA platform (Definiens, Munich Germany). NLST provided up to three 
reconstructions for each time point. The reconstruction chosen by scanner type is found in 
Supplemental Table 4. Using an automated segmentation algorithm reduces intra-observer 
variations; however relying on a radiologist to find the nodules means there is inter-observer 
variation.
Features
There were 219 3-D image features extracted from the baseline scan. A challenge for high-
dimensional feature data is over-fitting by having too many features and too few subjects. 
Hence, there is a need to prioritize features that: 1) aren’t redundant, 2) have a large inter-
subject biological range, and 3) are stable. In prior work, we studied stability of quantitative 
features under repeated (“coffee break”) scans and found some of the stable features are 
prognostic and predictive10,11.
Classifier Modeling
WEKA12 was used to build and test classifiers. We compared J48, JRIP, Naïve Bayes, 
support vector machines (SVM), and Random Forest(s). J48 is a decision tree classifier13. 
The confidence factor for error-based pruning was set to 0.25. JRIP is a rule learner14. Naïve 
Bayes15 is a probabilistic classifier. Support vector machines16 project the data into a multi-
dimensional space to separate classes with a hyper plane. We used libSVM as our 
implementation of support vector machines17. Both linear and radial basis function kernels 
were used in building a support vector machine. Cost and gamma parameters were tuned on 
training data with a grid search. The random forests classifier is an ensemble classifier that 
produces multiple decision trees. The number of decision trees used was 20018. When doing 
cross validation experiments, two filter feature selection methods were run per fold before 
classification: relief-f19–21 and correlation-based feature subset selection (CFS)22. Relief-f 
used a ranker search method. CFS used a greedy stepwise search method.
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RESULTS
We test the hypothesis that radiomic analyses of screening CTs at baseline can accurately 
predict which IPNs will subsequently develop into clinical cancers. The workflow of our 
study is presented in Supplemental Figure 1. According to NCCN23 and ACR24 guidelines, 
the method of choice to distinguish cancerous from benign nodules is to measure nodule 
growth following a subsequent screening session after 7–12 months: those with significant 
growth, 1.5mm or greater24, are classified as cancerous. Figure 2 presents two nodules at 
baseline and after a subsequent 1-year follow-up screen. Notably, there was nothing obvious 
to distinguish the benign (upper) from cancerous (lower) IPNs at baseline. Hence, they were 
both characterized as IPNs in the T0 baseline screen. The radiomics features show a few of 
the most divergent measures, including relative volume of air spaces and mean attenuation. 
Notably, baseline volume was larger in the benign nodule in this case.
Feature Stability
We prioritized a set of features from the RIDER data set, which consisted of two non-
enhanced CT scans of the same patients taken 15 minutes apart with the same scanner 
settings. From these analyses, 23 features (Supplemental Table 5) exhibited a concordance 
correlation coefficient (CCC) of ≥ 0.9510,11. The most stable feature category contained 
nodule size descriptors, where 84% of the features showed concordance ≥ 0.95. Texture 
features demonstrated lower levels of concordance due to their high dependence on the CT 
attenuations. Scanner parameter settings such as field of view, which affects pixel size, also 
affect textures. A histogram of the pixel sizes for each of our cohorts is provided in 
Supplemental Figure 2, showing that there was a large amount of variability in the data sets. 
While such variability may not adversely affect a radiologists’ ability to provide qualitative 
assessment, it will likely affect the ability to extract quantitative radiomic data. Further, 
although the protocol specified a slice thickness of 2.0 mm, it can be seen in Supplemental 
Figure 3 that the majority were 2.5 mm and above, which also may impact the extraction of 
radiomic data. Nonstandardized acquisitions are one known limitation in large multi-center 
trials like the NLST. In radiomics, all these variations add to feature description noise and 
influence prediction accuracy. Re-interpolation of the data to a fixed voxel size is possible, 
but generates noise that cannot be compensated25.
Classifier Models
As presented in Table 2 the best accuracy for predicting development of cancer one year 
hence (at T1) using baseline scans was 80.1% (AUC = 0.83; FPR = 9%) using a random 
forests classifier with RIDER prioritized features26. We used the Wilcoxon signed-rank 
test27 on the results of thirty 10-fold cross validations using the best volume classifier and 
best all feature classifier. Significance was found at the 0.01 level for our full feature 
approach with the top classifiers compared to volume for both accuracy and AUC. However, 
we did try other tests such as the 5x2 fold cross validation followed by an F-test28 , finding 
significance at the 0.05 level for only a subset of random seeds. We believe with more data 
our approach will always be statistically significantly better than volume. Supplemental 
Table 6 shows full results for cohort 1.
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The best shows the top accuracy of 78.7% (AUC = 0.75; FPR = 11%) for predicting 
development of cancer 2 years hence (at T2). This accuracy was achieved with support 
vector machines using a radial basis function kernel with RIDER-prioritized features and 
feature selection with relief-f to find the 10 best features. Using Wilcoxon’s signed-rank 
test27 on 30 10-fold cross validations showed this result to be better than volume, which had 
an accuracy of 71.4%, at the 0.01 level. Full results for cohort 2 are in Supplemental Table 7. 
It is understandable that a prediction further into the future in cohort 2 is not as accurate as 
cohort 1.
An alternative approach to cross validation is to use one cohort for training and the other for 
testing. Table 2 also shows the accuracy when training on SDLC and bPN T1 cohorts and 
testing on SDLC and bPN T2 cohorts. In this case, the best features were RIDER prioritized 
further sub-selected with Relief-f. These features were then used to build a random forests 
classifier and the classifier was applied to the previously unseen cohort 2, which yielded a 
top accuracy of 76.79% (AUC = 0.81; FPR = 18%). This relatively reduced accuracy is 
expected because the biology’s of cancers presenting 1 or 2 years hence are likely different. 
Using bagging29 to generate 30 training sets a Wilcoxon test27 showed significance over 
using volume alone with the top classifiers for AUC at the 0.01 level. With volume alone, 
using a JRIP classifier yielded an accuracy of 72.15%. Full results are presented in 
Supplemental Table 8.
Solidity
There were 58 nodules that were ground glass in appearance, 41 nodules that were semi-
solid, and 338 that were solid. Some nodules could not be scored. For a full break down see 
Supplemental Table 9. Across cohorts, 24 ground glass nodules became cancerous, 27 semi-
solid nodules became cancerous, and 85 solid nodules became cancerous. One of the 
limitations of this study is that nodules that are not solid may take longer than the study 
period to present as cancer.
Risk Score
The Lung Imaging Reporting and Data System (Lung-RADS) was developed by the 
American College of Radiology to standardize the screening of CT lung cancer images24 
into categories from benign to cancer., We performed Lung-RADS categorization on T0 
images from 58 pre-cancers and 127 benign nodules from SDLC-2 and bPN-2, respectively. 
Categories 3 and below were labeled as benign and categories 4A and 4B as malignant. The 
accuracy of lung-RADS in predicting the subsequent development of cancer was 71.4% 
(Table 3). Another risk score by McWilliams et al. (Brock University cancer prediction 
equation) utilizes age, sex, family history of cancer, presence of visually detected 
emphysema, nodule size, solidity, nodule location, number of nodules, and spiculation to 
generate a probability of cancer30. In the McWilliams et al. model, 5% risk is a low 
probability of developing cancer, intermediate is a 5% to 10% risk, and high is greater than 
10%. We applied this model to the same cohort 2 data that were scored for Lung-RADS. We 
labeled the first two groups as non-cancer and greater than 10% as cancer. The accuracy of 
this model was 78.9% (Table 3). To extend our radiomics model, we generated a risk score 
by categorizing individuals based on their probability of belonging to the malignant or 
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benign group. In our case, we separated low, intermediate low, intermediate high and high 
risk as quartiles. The results using a random forests classifier on the same data set are shown 
in Table 3. As shown, the radiomics approach performed very well for extreme phenotypes, 
with accuracies of 92% and 93% for predicting high and low risk, respectively. Although 
results in the intermediate groups were more equivocal, at 63–68%, the overall accuracy of 
automatically extracted features was 80.0%, compared to McWilliams, 78.9%, and Lung-
RADS 71.4%. We also compared the radiomics approach to using volume as the only 
feature, which had an accuracy of 71.8%. Using McNemar’s test31, the radiomics result is 
significantly better than Lung-RADS, two-tailed p=0.0177, and better than classification 
with the same models using volume as the only feature, two-tailed p=0.025, but not 
significantly better than McWilliams, two-tailed p=0.8383. However, the radiomics model 
has the added benefit to radiologists of being automated after the nodule has been found for 
segmentation for a given nodule. Figure 3 shows the ROC curves for the McWilliams 
approach, which has an AUC of 0.67, volume, which has an AUC of 0.74, and the radiomics 
scoring schema, which has an AUC of 0.87.
Discussion
The long-term vision for this work is to qualify the application of radiomic biomarkers to 
reduce over-diagnosis and over-treatment of screen- and incidentally-detected lung nodules. 
It can be envisioned that these radiomics risk scores can be used now to prescribe optimal 
time for follow up scans for definitive differential diagnosis. Hence, a subject with a low risk 
score could be scanned less often than one with a high score. The current results show that a 
subset of radiomic features extracted from indeterminate pulmonary nodules at a baseline 
CT screening scan can be used to predict the subsequent occurrence of cancer or non-cancer 
with an overall accuracy of 80%. Importantly, this approach has an accuracy >90% when 
predicting extreme benign and malignant phenotypes; classifications that include more than 
half of the subjects in this study. Currently, prediction of lung cancer risk in a screening 
setting is achieved using the Lung-RADSTM system, which classifies risk of cancer from CT 
scans based on size, solidity and location. Lung-RADs was developed for lung cancer 
screening by the American College of Radiology, ACR24. Although Lung-RADSTM was not 
used in the NLST for prospective structured reporting, it was recently evaluated in a large 
retrospective study32, resulting in a decrease in FPR from 26.6% to 12.8%; hence a 
significant reduction in the overdiagnosis and overtreatment. Sensitivity of detecting a 
cancer was lower for Lung-RADS vs. the NLST (84.9% vs. 93.5%) and this did not 
appreciably improve upon subsequent follow-up scans. In comparison, the radiomics 
approach herein achieved FPRs of 9% and 11%, sensitivities of 58% and 60% and 
specificities of 91% and 89% at baseline to predict subsequent cancer 1 and 2 years hence, 
respectively. The most advanced molecular technique used serum miRNA to achieve a 
prediction sensitivity of 87% and specificity of 81%.33 However, most of their sampling was 
done at the time of diagnosis (50 of 69), so its ability to predict across time is unknown. It 
should be noted that our case-control design has a 2:1 mixture of bPN to SDLC for training, 
which leads to a lower FPR, however the training mixture could be changed and so this 
measurement is reported.
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These results must be tempered by acknowledging the limitations to the current study, and 
areas for improvement exist. The biggest limitations to the current study were cohort sizes, 
non-standardization of image acquisition, and the lack of clinical or molecular data. 
Although there were 26,722 subjects in the LDCT arm of the NLST, only 206 of these 
subjects developed screen-detected lung cancers (SDLC) following a nodule-positive screen. 
Hence, with these relatively small numbers it is difficult to accommodate co-variates of 
patient characteristics. We controlled for these by demographic matching the cohorts under 
study, but this did not allow for analysis of the individual subjects with greater granularity. 
At baseline, there were a total of 6,921 NLST participants who had nodule-positive/cancer-
negative screens, with 6,715 having IPNs that did not develop into lung cancer. Hence, the 
ratio of non-cancer to eventual-cancer of an IPN at baseline is ~32:1. In our cohort analyses, 
we compared non-cancer to eventual-cancer at a ratio of 2:1 and hence, there was a false 
discovery bias emanating from the proportionalities in our study population. While the 
nested cohort design limits confounding factors, it may also limit extrapolation to the larger 
NLST population. Regarding non-standard imaging, although exams in the NLST were 
supposed to be reconstructed to a slice thickness of 2.0 mm, the actual thickness varied from 
1 to 5 mm; fields of view (FOV) varied significantly between and within patients 
(Supplemental Figures 2, 3); and reconstruction kernels are not comparable between 
manufacturers (Supplemental Table 4). These issues limit the potential power of radiomics. 
A further limitation is the time required to curate the database, identify the lesions and 
extract the features. In theory, these could be reduced if the data curation and nodule 
identification occurred at the time of the primary radiology read, the so-called “Radiology 
Reading Room of the Future”25. Nonetheless, even with these caveats, radiomic-based 
classifier models and risk assessments exhibited significant power to identify those patients 
with IPNs at baseline who are most or least, likely to develop cancer. Moving forward, 
features are being qualified based on their sensitivity to reconstruction kernels and overly 
sensitive features can be removed during dimensionality reduction. With very large data sets, 
these can be parsed as co-variates. While it will be preferable to acquire all images with 
standardized fields of view and reconstruction matrixes, this is proving to be impractical. To 
accommodate inter-subject differences, pixel sizes can be regularized by interpolation.
To rectify these deficits large databases will be needed. An important opportunity will be the 
ACR based Lung Cancer Screening Registry (LCSR) to capture screening metadata. Therein 
will be an opportunity to develop a federated, living database of images and radiomic data so 
that co-variates and evolving acquisition standards can be accommodated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Flowchart of cohorts
Both Cohorts 1 and 2 had a nodule-positive/cancer negative screen at time 0. Cohort 1 had a 
nodule positive screen at Time 1, of which 104 were diagnosed with a screen-detected lung 
cancer, SDLC. These were demographically matched to subjects with benign pulmonary 
nodules, bPN, and the same screening history. 208 bPN-1 were identified, and of these, 176 
were successfully segmented. Cohort 2 had a nodule-positive/cancer negative screen at time 
1, followed by a nodule- positive screen at Time 2, of which 92 had SDLC. These were 
demographically matched to 184 bPN subjects, of which 152 were successfully segmented. 
Segmentation errors are presented in Supplemental Table 1.
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Figure 2. Images from SDLC and bPN at T0 and T1
The top images are from a patient with a benign pulmonary nodule, bPN, in cohort 1. The 
bottom images are from a patient with a screen-detected lung cancer, SDLC group, in cohort 
1. The T0 scans appear similar to the eye, and growth can clearly be seen on the T1 SDLC 
scan, relative to no growth of the T1 bPN scan. Select radiomic features from the T0 scans 
that discriminated the groups are shown in the text boxes.
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Figure 3. Binary classifier prediction
Receiver operator characteristics (ROC) curves of risk scores for McWilliams, our Random 
Forests based approach, and volume are shown (see text for details). McWilliams had an 
area under the ROC of 0.67 and volume had an AUC of 0.74, whereas the radiomics 
classifier using Random Forests had an AUC of 0.87.
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Table 1
Demographics and Clinical Characteristics of NLST Cohort Cases
Characteristic Lung Cancer Cases (N = 170) Nodule-Positive Controls (N = 328) P-value1
Age, mean (SD) 63.7 (5.11) 63.5 (5.1) 0.66
Sex, N (%)
 Male 94 (55.3) 192 (58.5)
 Female 76 (44.7) 136 (41.5) 0.28
Race, N (%)
 White 161 (94.7) 315 (96.0)
 Black, Asian, Other 9 (5.3) 13 (4.0) 0.49
Ethnicity, N (%)
 Hispanic or Latino 0 (0.0) 2 (0.6)
 Neither Hispanic/Latino and 170 (100.0) 326 (99.4) 0.55
 Unknown
Smoking, N (%)
 Current 89 (53.4) 175 (53.4)
 Former 81 (47.6) 153 (46.6) 0.85
Pack-Years Smoked, mean (SD)
 Current smokers 63.2 (25.8) 62.0 (21.3) 0.69
 Former smokers 64.5 (27.6) 63.7 (26.8) 0.83
Self-Reported History of COPD, N (%)
 Yes 13 (7.6) 19 (5.8)
 No 157 (92.4) 309 (94.2) 0.44
FH of Lung Cancer, N (%)
 Yes 41 (24.1) 56 (17.1)
 No 129 (75.9) 272 (82.9) 0.07
Stage, N (%)
 I 117 (68.8) --
 II 12 (7.1) --
 III 21 (12.3) --
 IV 18 (10.6) --
 Carcinoid, Unknown 2 (1.2) -- --
Histology, N (%)
 Adenocarcinoma 108 (63.5) --
 Squamous cell carcinoma 38 (22.4) --
 Other, NOS, Unknown 24 (14.1) -- --
Abbreviations: COPD = chronic obstructive pulmonary disease; FH = Family history;
1
P-values calculated using Fisher’s exact test for categorical variables, Student’s t-test for continuous variables
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